These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26329980)

  • 1. Time-to-onset and -resolution of adverse events before/after atomoxetine discontinuation in adult patients with ADHD.
    Upadhyaya H; Tanaka Y; Lipsius S; Kryzhanovskaya LA; Lane JR; Escobar R; Trzepacz PT; Allen AJ
    Postgrad Med; 2015; 127(7):677-85. PubMed ID: 26329980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials.
    Camporeale A; Porsdal V; De Bruyckere K; Tanaka Y; Upadhyaya H; Deix C; Deberdt W
    J Psychopharmacol; 2015 Jan; 29(1):3-14. PubMed ID: 25424623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies.
    Wietecha LA; Ruff DD; Allen AJ; Greenhill LL; Newcorn JH
    J Clin Psychiatry; 2013 Mar; 74(12):1217-23. PubMed ID: 24434090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder.
    Hirata Y; Goto T; Takita Y; Trzepacz PT; Allen AJ; Ichikawa H; Takahashi M
    Asia Pac Psychiatry; 2014 Sep; 6(3):292-301. PubMed ID: 24376099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.
    Lee SI; Song DH; Shin DW; Kim JH; Lee YS; Hwang JW; Park TW; Yook KH; Lee JI; Bahn GH; Hirata Y; Goto T; Takita Y; Takahashi M; Lee S; Treuer T
    Asia Pac Psychiatry; 2014 Dec; 6(4):386-96. PubMed ID: 25345739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder.
    Takahashi M; Goto T; Takita Y; Chung SK; Wang Y; Gau SS
    Asia Pac Psychiatry; 2014 Mar; 6(1):62-70. PubMed ID: 23857916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
    Handen BL; Aman MG; Arnold LE; Hyman SL; Tumuluru RV; Lecavalier L; Corbett-Dick P; Pan X; Hollway JA; Buchan-Page KA; Silverman LB; Brown NV; Rice RR; Hellings J; Mruzek DW; McAuliffe-Bellin S; Hurt EA; Ryan MM; Levato L; Smith T
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):905-15. PubMed ID: 26506581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: a pooled analysis.
    Camporeale A; Day KA; Ruff D; Arsenault J; Williams D; Kelsey DK
    Drug Saf; 2013 Aug; 36(8):663-71. PubMed ID: 23775507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study.
    Adler L; Tanaka Y; Williams D; Trzepacz PT; Goto T; Allen AJ; Escobar R; Upadhyaya HP
    J Clin Psychopharmacol; 2014 Aug; 34(4):461-6. PubMed ID: 24977716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
    Montoya A; Hervas A; Cardo E; Artigas J; Mardomingo MJ; Alda JA; Gastaminza X; García-Polavieja MJ; Gilaberte I; Escobar R
    Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse Events of Atomoxetine in a Double-Blind Placebo-Controlled Study in Children with Autism.
    Tumuluru RV; Corbett-Dick P; Aman MG; Smith T; Arnold LE; Pan X; Buchan-Page KA; Brown NV; Ryan MM; Hyman SL; Hellings J; Williams C; Hollway JA; Lecavalier L; Rice RR; McAuliffe-Bellin S; Handen BL
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):708-714. PubMed ID: 28509573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD.
    Adler L; Dietrich A; Reimherr FW; Taylor LV; Sutton VK; Bakken R; Allen AJ; Kelsey D
    Ann Clin Psychiatry; 2006; 18(2):107-13. PubMed ID: 16754416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
    Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
    J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular effects of atomoxetine in children, adolescents, and adults.
    Wernicke JF; Faries D; Girod D; Brown J; Gao H; Kelsey D; Quintana H; Lipetz R; Michelson D; Heiligenstein J
    Drug Saf; 2003; 26(10):729-40. PubMed ID: 12862507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Atomoxetine Hydrochloride in Asian Adults With ADHD.
    Goto T; Hirata Y; Takita Y; Trzepacz PT; Allen AJ; Song DH; Gau SS; Ichikawa H; Takahashi M
    J Atten Disord; 2017 Jan; 21(2):100-109. PubMed ID: 24203774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression.
    Liang EF; Lim SZ; Tam WW; Ho CS; Zhang MW; McIntyre RS; Ho RC
    Int J Environ Res Public Health; 2018 Aug; 15(8):. PubMed ID: 30127314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.